ArticleSarcoma2018
Myxoid Liposarcoma: Treatment Outcomes from Chemotherapy and Radiation Therapy.
Article in Sarcoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.JAMA oncology · 2021Trial
- Review
- Myxoid liposarcoma: treatment outcomes, metastatic pattern and volumetric analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Silently Wrapped: Embolization and Surgical Strategy for Giant Sciatic-Sparing Myxoid Liposarcoma-Case Report.Reports (MDPI) · 2025Article
- Evaluation of Prognostic Factors in Myxoid Liposarcoma Treated with Combined Neoadjuvant Radiotherapy and Surgical Excision: Systematic Review.Diseases (Basel, Switzerland) · 2025Review
- Histology-Tailored Approach to Soft Tissue Sarcoma.Annals of surgical oncology · 2024Review
- Myxoid Liposarcomas of the Thigh: Pre-Operative Presentation, Clinical Outcomes, and Functional Results of Surgical Treatment.Healthcare (Basel, Switzerland) · 2024Article
- Significance of radiation therapy in the myxoid round-cell liposarcoma treatment regimen.International journal of clinical oncology · 2024Article
- An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.Journal of molecular histology · 2024Review
- Patterns of Metastatic Recurrence of Genetically Confirmed Myxoid Liposarcoma.Annals of surgical oncology · 2023Review
- Surgical management of giant recurrent retroperitoneal liposarcoma: a case report and review of the literature.Annals of medicine and surgery (2012) · 2023Article
- Myxoid Liposarcomas: Systemic Treatment Options.Current treatment options in oncology · 2023Review
- Primary renal myxoid liposarcoma with pancreatic invasion onFrontiers in medicine · 2023Article
- Myxoid Liposarcoma of the Vulva: A Rare Malignancy Mimicking Benign Vulvar Mass.The American journal of case reports · 2022Article
- Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience.South Asian journal of cancer · 2022Article
- Myxoid liposarcoma originating in the retroperitoneum with metastasis to the calcaneus: a rare case report and review of literature.Skeletal radiology · 2022Review
- Radiotherapy, volume reduction, and short-term surgical outcomes in the treatment of large myxoid liposarcomas.Radiation oncology journal · 2022Article
- Artificial intelligence significantly improves the diagnostic accuracy of deep myxoid soft tissue lesions in histology.Scientific reports · 2022Article
- Preoperative Radiation for Soft Tissue Sarcomas: How Much Is Needed?Current treatment options in oncology · 2022Review
- Association between biologically effective dose and local control after stereotactic body radiotherapy for metastatic sarcoma.Journal of radiosurgery and SBRT · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMyxoid liposarcoma (MLS) is a subtype of liposarcoma characterized morphologically by lipomatous differentiation with a myxoid stroma. The purpose of this study was to review clinical and pathological information for patients treated for MLS at our institution to better understand neoadjuvant and adjuvant therapy. MATERIALS AND
methodsAn institutional database of sarcomas was queried for patients who were treated for MLS at our institution between 1992 and 2013. Survival curves were constructed using Kaplan-Meier analysis, and univariate and multivariate statistics were performed using the Cox-proportional hazards model and using linear regression.
resultsA total of 85 patients with myxoid liposarcoma were identified. The mean and median histologic response rate to treatment for patients who received preoperative radiation therapy was 77.6%. Five-year disease-free survival, distant metastasis-free survival, local recurrence-free survival, and overall survival were 78.6% (95% CI: 67.8-86.1), 84.7% (95% CI: 74.5-91.0), 95.6% (95% CI: 86.9-98.6), and 87.5% (95% CI: 77.2-93.3) respectively. On univariate analysis, there was a trend towards higher necrosis or treatment response rates in patients who received concurrent chemotherapy, 84.7% (95% CI: 75.9-93.4) and 69.5% (95% CI: 55.1-83.8),
conclusionsMyxoid liposarcoma exhibits histological response to chemotherapy and radiation therapy. Tumor size appears to be greatest predictor of long-term disease control and overall survival. We were not able to show that chemotherapy provides a clinical benefit with regard to local control, disease-free survival, or overall survival. However, it is important to note that the selected usage of chemotherapy in the highest risk patients confounds this analysis. Further investigation is needed to help better determine the optimal use of chemotherapy in this group of patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.